Evaluation of the immunogenicity and protective efficacy of a recombinant CS6-based ETEC vaccine in an Aotus nancymaae CS6 + ETEC challenge model.

[1]  M. T. Orr,et al.  The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine , 2019, npj Vaccines.

[2]  M. Prouty,et al.  Biochemical and Immunological Evaluation of Recombinant CS6-Derived Subunit Enterotoxigenic Escherichia coli Vaccine Candidates , 2019, Infection and Immunity.

[3]  E. Hall,et al.  Establishment, Validation, and Application of a New World Primate Model of Enterotoxigenic Escherichia coli Disease for Vaccine Development , 2018, Infection and Immunity.

[4]  C. Murray,et al.  Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016 , 2018, The Lancet. Infectious diseases.

[5]  A. Macpherson,et al.  Analysis of bacterial-surface-specific antibodies in body fluids using bacterial flow cytometry , 2016, Nature Protocols.

[6]  E. Hall,et al.  Immunogenicity of a prototype enterotoxigenic Escherichia coli adhesin vaccine in mice and nonhuman primates. , 2016, Vaccine.

[7]  M. Petzold,et al.  Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study. , 2014, Vaccine.

[8]  Verónica Ambriz-Aviña,et al.  Applications of Flow Cytometry to Characterize Bacterial Physiological Responses , 2014, BioMed research international.

[9]  H. Dupont,et al.  Persistent abdominal symptoms in US adults after short-term stay in Mexico. , 2014, Journal of travel medicine.

[10]  M. Lebens,et al.  Construction of a non-toxigenic Escherichia coli oral vaccine strain expressing large amounts of CS6 and inducing strong intestinal and serum anti-CS6 antibody responses in mice. , 2011, Vaccine.

[11]  M. Riddle,et al.  A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. , 2011, Vaccine.

[12]  D. Tribble,et al.  A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC). , 2011, Vaccine.

[13]  J. Clements,et al.  Characterization of a Mutant Escherichia coli Heat-Labile Toxin, LT(R192G/L211A), as a Safe and Effective Oral Adjuvant , 2011, Clinical and Vaccine Immunology.

[14]  R. Frenck,et al.  The epidemiology of travelers' diarrhea in Incirlik, Turkey: a region with a predominance of heat-stabile toxin producing enterotoxigenic Escherichia coli. , 2010, Diagnostic microbiology and infectious disease.

[15]  A. Svennerholm,et al.  Vaccines against enterotoxigenic Escherichia coli , 2008, Expert review of vaccines.

[16]  E. Hall,et al.  Randomized Clinical Trial Assessing the Safety and Immunogenicity of Oral Microencapsulated Enterotoxigenic Escherichia coli Surface Antigen 6 with or without Heat-Labile Enterotoxin with Mutation R192G , 2008, Clinical and Vaccine Immunology.

[17]  M. Wolf,et al.  Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli , 2006, Infection and Immunity.

[18]  M. Riddle,et al.  Postinfectious Irritable Bowel Syndrome—A Meta-Analysis , 2006, The American Journal of Gastroenterology.

[19]  A. Faruque,et al.  Enterotoxigenic Escherichia coli in Developing Countries: Epidemiology, Microbiology, Clinical Features, Treatment, and Prevention , 2005, Clinical Microbiology Reviews.

[20]  M. Wolf,et al.  Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. , 2003, Vaccine.

[21]  H. Dupont,et al.  Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. , 2006, Journal of travel medicine.

[22]  M. Wolf,et al.  Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously , 2002, Infection and Immunity.

[23]  A. Faruque,et al.  Prevalence of Toxin Types and Colonization Factors in Enterotoxigenic Escherichia coli Isolated during a 2-Year Period from Diarrheal Patients in Bangladesh , 2000, Journal of Clinical Microbiology.

[24]  J. Clements,et al.  The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). , 1999, Vaccine.